Vertex Pharmaceuticals Inc.

Company Snapshot

Founded: 1989

Entity Type: Public

Employees: 6,400

Region: U.S.

Revenue: $12,001.3 Millions

Revenue Year: 2025

Headquarter: Massachusetts, U.S.

Key Geographics: U.S., Europe, Other

Corporate Address: 50 Northern Avenue, Boston, Massachusetts 02210 U.S. Tel. +1-617-341-6100 www.vrtx.com

Company Overview

Vertex Pharmaceuticals Inc. is a global biotechnology company offering advanced scientific innovation to develop transformative medicines for individuals with serious diseases, particularly in specialty markets. Its portfolio includes four approved therapies that treat the underlying cause of cystic fibrosis (CF), a life-threatening genetic disorder. In addition, it has an approved gene-editing therapy, Casgevy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), both of which are severe inherited blood disorders. Its pipeline features clinical-stage programs targeting CF, SCD, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency. It is also researching a novel treatment approach for Duchenne muscular dystrophy based on CRISPR/Cas9 gene-editing technology.

Financial Highlights (FY 2025)

Net Revenue: ***

Total Current Liabilities: ***

Total Current Assets: ***

R&D expenses: ***

Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Vertex Pharmaceuticals Inc. In Reports

Emerging Drugs: Global Markets

BCC Research detailed report on Emerging Drugs Markets revenue ($ Million) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030.

Global DNA Read, Write, and Edit Market

BCC Research detailed report on DNA Read, Write and Edit Market includes global revenue ($ Million) for the base year 2024 and estimated data for the forecast period 2025 through 2030.

Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing

According to BCC Research detailed report on Genetic Modification Therapies Market includes global revenue ($ Million) for the base year 2024 and estimated data for the forecast period 2025 through 2030.

View All Reports

Vertex Pharmaceuticals Inc. In News

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat

MarketBeat - Aug 08, 2026

How Vertex Regained Its Footing On A Competitor's Bullish Report - Investor's Business Daily

Investor's Business Daily - Aug 07, 2026

Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ... - Yahoo Finance

Yahoo Finance - Aug 04, 2026

Vertex raises annual revenue forecast on cystic fibrosis drugs strength - Reuters

Reuters - Aug 03, 2026

Read All News

Company's Business Segments

TRIKAFTA/KAFTRIO : Elexacaftor/Tezacaftor/Ivacaftor, Ivacaftor
ALYFTREK : vanzacaftor/tezacaftor/deutivacaftor
Other product revenue : CASGEVY, JOURNAVX, KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other revenue : Licencese revenue

Applications/End User Industries

Healthcare

Pharmaceuticals

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment